Pantavou K, Yiallourou AI, Piovani D, et al. - In moderate-to-severe ulcerative colitis (UC; an inflammatory disease of the colon and rectum with remissions and relapses), researchers tested the safety and effectiveness of biologic agents and tofacitinib through systematically searching PubMed, Embase, Scopus, and the Cochrane Library to identify meta-analyses of randomized controlled trials. They analyzed adalimumab, golimumab, infliximab, vedolizumab, and tofacitinib in UC. According to results, indirect comparisons suggested that infliximab could be better for inducing clinical response and mucosal healing than adalimumab and golimumab. For the treatment of UC, biologics and tofacitinib are effective and safe. Such results can assist in making medical decisions. Safety analysis showed no increase in adverse event rates, except for infliximab.